title: Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects.
abstract: We studied the pharmacokinetics of moguisteine, a racemic non-narcotic peripheral antitussive drug, in 12 healthy male subjects after a single oral administration of 200 mg. The unchanged drug was absent in plasma and urine of all subjects. Moguisteine was immediately and completely hydrolyzed to its main active metabolite, the free carboxylic acid M1. Therefore, we evaluated the kinetic profiles of M1, of its enantiomers R(+)-M1 and S(-)-M1, and of M1 sulfoxide optical isomers M2/I and M2/II by conventional and stereospecific HPLC. Maximum plasma concentrations for M1 (2.83 mg/l), M2/I (0.26 mg/l) and M2/II (0.40 mg/l), were respectively reached at 1.3, 1.6 and 1.5 h after moguisteine administration. Plasma concentrations declined after the peak with mean apparent terminal half-lives of 0.65 h (M1), 0.88 h (M2/I) and 0.84 h (M2/II). Most of the administered dose was recovered in urine within 6 h from moguisteine treatment. The systemic and renal clearance values indicated high renal extraction ratio for all moguisteine metabolites, and particularly for M1 sulfoxide optical isomers. Plasma concentration-time profiles and urinary excretion patterns for M1 enantiomers R(+)-M1 and S(-)-M1 were quite similar. Thus, for later moguisteine pharmacokinetic evaluations the investigation of the plasma concentration-time curve and the urinary excretion of the sole racemic M1 through non-stereospecific analytical methods may suffice in most cases.
authors.affiliation: Research Center, Boehringer Mannheim Italia SpA, Monza, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bernareggi
authors.forename: A
authors.initials: A
authors.lastname: Crema
authors.forename: R M
authors.initials: RM
authors.lastname: Carlesi
authors.forename: D
authors.initials: D
authors.lastname: Castoldi
authors.forename: E
authors.initials: E
authors.lastname: Ratti
authors.forename: M I
authors.initials: MI
authors.lastname: Renoldi
authors.forename: D
authors.initials: D
authors.lastname: Ratti
authors.forename: R
authors.initials: R
authors.lastname: Ceserani
authors.forename: S
authors.initials: S
authors.lastname: Tognella
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000996:Antitussive Agents / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics* / Q000652:urine; D006801:Humans; D008297:Male; D013237:Stereoisomerism; D013844:Thiazoles / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics* / Q000652:urine; D053778:Thiazolidines
chemical_list: D000996:Antitussive Agents; D013844:Thiazoles; D053778:Thiazolidines; C087933:moguisteine